In my capacity as Chief Executive Officer, I am pleased to invite you to your Annual General Meeting to be held on April 26, 2017 at the head offices of Onxeo. This is a privileged moment that will allow us to present to you the progress of our projects and to share with you our vision of the future of Onxeo, while allowing you to contribute thanks to your vote, in Person, by proxy or by correspondence. In 2016, we continued to deploy our strategy to transform Onxeo into a leading biotechnology company in oncology. We have enriched our portfolio with a very valuable strategic asset thanks to the acquisition of DNA Therapeutics and the AsiDNATM product, a gem that puts Onxeo at the forefront of technology in the field of tumor DNA repair inhibition. We also finalized the recruitment of patients in ReLive, the phase III study of Livatag® in the 2nd line treatment of advanced hepatocellular carcinoma (HCC), whose preliminary results are expected mid-2017. Finally, we initiated an ambitious plan for belinostat (Beleodaq®) to evaluate its potential in new indications, beyond the treatment of peripheral T cell lymphoma (PTCL) for which it is already marketed in the United States.
To pursue our strategy and allow us to create - through each of our programs - this value for our shareholders, your vote and your support for the resolutions presented to the General Meeting are essential, as these resolutions are the necessary tools to move forward, better structure and ultimately manage the company. We invite you to visit the section of this site dedicated to your General Meeting where you will find all the necessary information to participate in this General Meeting. We count on you and thank you for your trust.